McKesson Q2 FY26: where the revenue came from and where it went
The whole income statement of McKesson for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2025
- Reported
- Nov 6, 2025
Revenue$103.15B
+10% year over year
Gross profit$3.54B
3% margin
Operating profit$1.41B
1% margin
Net profit$1.11B
1% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 103.15 | 100% | +10% |
| North american | 86.48 | 84% | |
| Oncology & multispecialty | 12.04 | 12% | |
| Medical-Surgical | 2.95 | 3% | |
| Prescription technology | 1.38 | 1% | |
| Other revenue | 0.30 | 0% | |
| Cost of revenue | −99.61 | 97% | |
| Gross profit | 3.54 | 3% margin | +0pp |
| SG&A | −2.07 | 2% | −1pp |
| Other | −0.06 | 0% | +0pp |
| Operating profit | 1.41 | 1% margin | +1pp |
| Interest & other costs | −0.07 | ||
| Tax | −0.23 | ||
| Net profit | 1.11 | 1% margin | +1pp |
124 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest